Year |
Citation |
Score |
2022 |
Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. Withdrawal: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. The Journal of Biological Chemistry. 298: 102126. PMID 35738192 DOI: 10.1016/j.jbc.2022.102126 |
0.388 |
|
2014 |
Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. Journal of Translational Medicine. 12: 307. PMID 25367255 DOI: 10.1186/S12967-014-0307-X |
0.38 |
|
2013 |
Rosen PJ, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg RD, Shubhakar P, Zoog S, Beaupre DM, Lee P. First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 41. PMID 28137005 DOI: 10.1200/Jco.2013.31.6_Suppl.41 |
0.314 |
|
2011 |
Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation. 121: 1298-312. PMID 21436587 DOI: 10.1172/Jci43414 |
0.47 |
|
2010 |
Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, N.Y.). 12: 116-27. PMID 20126470 DOI: 10.1593/Neo.91384 |
0.509 |
|
2009 |
Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Research. 69: 1685-92. PMID 19176388 DOI: 10.1158/0008-5472.Can-08-2164 |
0.555 |
|
2008 |
van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta KJ, Loberg RD. CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. Journal of Cellular Biochemistry. 104: 1587-97. PMID 18646053 DOI: 10.1002/Jcb.21652 |
0.526 |
|
2008 |
Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry. 105: 370-80. PMID 18636554 DOI: 10.1002/Jcb.21835 |
0.525 |
|
2008 |
Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta KJ, Taichman RS. An in vivo mouse model for human prostate cancer metastasis. Neoplasia (New York, N.Y.). 10: 371-80. PMID 18392141 DOI: 10.1593/Neo.08154 |
0.496 |
|
2008 |
Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. The Journal of Biological Chemistry. 283: 4283-94. PMID 18057003 DOI: 10.1074/Jbc.M707465200 |
0.522 |
|
2008 |
Craig M, Ying C, Loberg RD. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. Journal of Cellular Biochemistry. 103: 1-8. PMID 17541941 DOI: 10.1002/Jcb.21379 |
0.494 |
|
2008 |
Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS. Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow Blood. 112: 552-552. DOI: 10.1182/Blood.V112.11.552.552 |
0.433 |
|
2007 |
Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia (New York, N.Y.). 9: 1030-7. PMID 18084610 DOI: 10.1593/Neo.07778 |
0.486 |
|
2007 |
Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research. 67: 9417-24. PMID 17909051 DOI: 10.1158/0008-5472.Can-07-1286 |
0.521 |
|
2007 |
Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. The Journal of Clinical Investigation. 117: 2351-61. PMID 17786228 DOI: 10.1172/Jci31791 |
0.504 |
|
2007 |
Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (New York, N.Y.). 9: 556-62. PMID 17710158 DOI: 10.1593/Neo.07307 |
0.551 |
|
2007 |
Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due to malignancy. Ca: a Cancer Journal For Clinicians. 57: 225-41. PMID 17626119 DOI: 10.3322/Canjclin.57.4.225 |
0.412 |
|
2007 |
Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. Journal of Cellular Biochemistry. 101: 1292-300. PMID 17492768 DOI: 10.1002/Jcb.21252 |
0.538 |
|
2007 |
Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis Cancer and Metastasis Reviews. 25: 573-587. PMID 17165132 DOI: 10.1007/S10555-006-9019-X |
0.487 |
|
2006 |
Giles R, Loberg RD. Can we target the chemokine network for cancer therapeutics? Current Cancer Drug Targets. 6: 659-70. PMID 17168671 DOI: 10.2174/156800906779010245 |
0.428 |
|
2006 |
Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Reviews. 25: 611-9. PMID 17160712 DOI: 10.1007/S10555-006-9027-X |
0.485 |
|
2006 |
Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (New York, N.Y.). 8: 578-86. PMID 16867220 DOI: 10.1593/Neo.06280 |
0.561 |
|
2006 |
Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia (New York, N.Y.). 8: 69-78. PMID 16533428 DOI: 10.1593/Neo.05679 |
0.492 |
|
2006 |
Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ. Development of the VCaP androgen-independent model of prostate cancer. Urologic Oncology. 24: 161-8. PMID 16520280 DOI: 10.1016/J.Urolonc.2005.11.005 |
0.549 |
|
2005 |
Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology. 66: 1321-6. PMID 16360477 DOI: 10.1016/J.Urology.2005.06.094 |
0.466 |
|
2005 |
Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8232-41. PMID 16278478 DOI: 10.1200/Jco.2005.03.0841 |
0.578 |
|
2005 |
Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA, Pienta KJ. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. Journal of Cellular Biochemistry. 96: 641-52. PMID 16052512 DOI: 10.1002/Jcb.20533 |
0.522 |
|
2005 |
Pienta KJ, Loberg R. The “Emigration, Migration, and Immigration” of Prostate Cancer Clinical Prostate Cancer. 4: 24-30. PMID 15992458 DOI: 10.3816/Cgc.2005.N.008 |
0.543 |
|
2005 |
Loberg RD, Gayed BA, Olson KB, Pienta KJ. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Journal of Cellular Biochemistry. 96: 439-46. PMID 15988761 DOI: 10.1002/Jcb.20522 |
0.549 |
|
2005 |
Loberg RD, Neeley CK, Adam-Day LL, Fridman Y, St John LN, Nixdorf S, Jackson P, Kalikin LM, Pienta KJ. Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology International Journal of Oncology. 26: 1699-1705. PMID 15870888 DOI: 10.3892/Ijo.26.6.1699 |
0.538 |
|
2005 |
Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology. 65: 616-21. PMID 15780403 DOI: 10.1016/J.Urology.2004.10.053 |
0.483 |
|
2005 |
Macvicar GR, Loberg RD, Tantivejkul K, Pienta KJ. Growth factor and cytokine antibody array analysis of human hormone refractory prostate cancer (HRPC) tumor specimens and sera Journal of Clinical Oncology. 23: 4686-4686. DOI: 10.1200/Jco.2005.23.16_Suppl.4686 |
0.482 |
|
2005 |
Loberg RD, Pienta KJ. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer Urologic Oncology-Seminars and Original Investigations. 23: 76. DOI: 10.1016/J.Urolonc.2004.11.005 |
0.417 |
|
2005 |
Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA, Loberg RD, Pienta KJ. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA) Urologic Oncology-Seminars and Original Investigations. 23: 74. DOI: 10.1016/J.Urolonc.2004.11.002 |
0.483 |
|
2004 |
Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Letters. 215: 209-20. PMID 15488640 DOI: 10.1016/J.Canlet.2004.05.002 |
0.361 |
|
2004 |
Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia (New York, N.Y.). 6: 302-9. PMID 15256052 DOI: 10.1593/Neo.03484 |
0.478 |
|
2003 |
Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology. 62: 128-33. PMID 14747050 DOI: 10.1016/J.Urology.2003.10.026 |
0.444 |
|
Low-probability matches (unlikely to be authored by this person) |
2002 |
Loberg RD, Vesely E, Brosius FC. Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. The Journal of Biological Chemistry. 277: 41667-73. PMID 12200436 DOI: 10.1074/Jbc.M206405200 |
0.299 |
|
2008 |
Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. American Journal of Physiology. Cell Physiology. 295: C836-43. PMID 18650261 DOI: 10.1152/Ajpcell.00554.2007 |
0.294 |
|
2001 |
Heilig CW, Kreisberg JI, Freytag S, Murakami T, Ebina Y, Guo L, Heilig K, Loberg R, Qu X, Jin Y, Henry D, Brosius FC. Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression. American Journal of Physiology. Renal Physiology. 280: F657-66. PMID 11249857 DOI: 10.1152/Ajprenal.2001.280.4.F657 |
0.263 |
|
2001 |
Banes AK, Loberg RD, Brosius FC, Watts SW. Inability of serotonin to activate the c-Jun N-terminal kinase and p38 kinase pathways in rat aortic vascular smooth muscle cells. Bmc Pharmacology. 1: 8. PMID 11667949 DOI: 10.1186/1471-2210-1-8 |
0.262 |
|
2005 |
Park JL, Loberg RD, Duquaine D, Zhang H, Deo BK, Ardanaz N, Coyle J, Atkins KB, Schin M, Charron MJ, Kumagai AK, Pagano PJ, Brosius FC. GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 1596-602. PMID 15890973 DOI: 10.1161/01.Atv.0000170137.41079.Ab |
0.261 |
|
2003 |
Loberg RD, Northcott CA, Watts SW, Brosius FC. PI3-kinase-induced hyperreactivity in DOCA-salt hypertension is independent of GSK-3 activity. Hypertension. 41: 898-902. PMID 12629035 DOI: 10.1161/01.Hyp.0000061762.58873.2F |
0.254 |
|
2004 |
Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. The Journal of Pharmacology and Experimental Therapeutics. 309: 1011-9. PMID 14982964 DOI: 10.1124/Jpet.103.062265 |
0.248 |
|
2013 |
Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Molecular Cancer Therapeutics. 12: 2356-66. PMID 23990115 DOI: 10.1158/1535-7163.MCT-12-1178 |
0.206 |
|
2015 |
Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 6: 18693-706. PMID 26155941 DOI: 10.18632/Oncotarget.4472 |
0.201 |
|
2018 |
Hong DS, LoRusso PM, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel S, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients With Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30425090 DOI: 10.1158/1078-0432.CCR-18-1341 |
0.167 |
|
2017 |
Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, ... ... Loberg RD, et al. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28428191 DOI: 10.1158/1078-0432.CCR-16-2895 |
0.142 |
|
2016 |
Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer. PMID 27926778 DOI: 10.1002/Cncr.30437 |
0.123 |
|
2011 |
Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, et al. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. Journal of Medicinal Chemistry. 54: 8440-50. PMID 22087750 DOI: 10.1021/Jm200911R |
0.12 |
|
2016 |
de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, et al. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material. Plos One. 11: e0149405. PMID 26919633 DOI: 10.1371/journal.pone.0149405 |
0.108 |
|
2022 |
Pfeifer JD, Loberg R, Lofton-Day C, Zehnbauer BA. Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and Diagnostics. American Journal of Clinical Pathology. 157: 628-638. PMID 34871357 DOI: 10.1093/ajcp/aqab164 |
0.05 |
|
Hide low-probability matches. |